vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $359.9M, roughly 2.0× AdvanSix Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -0.8%, a 19.8% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 9.4%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $36.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ASIX vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $708.5M |
| Net Profit | $-2.8M | $135.1M |
| Gross Margin | 7.6% | — |
| Operating Margin | -0.7% | 21.6% |
| Net Margin | -0.8% | 19.1% |
| Revenue YoY | 9.4% | 32.0% |
| Net Profit YoY | -892.9% | 15.5% |
| EPS (diluted) | $-0.11 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $708.5M | ||
| Q3 25 | $374.5M | $659.9M | ||
| Q2 25 | $410.0M | $603.3M | ||
| Q1 25 | $377.8M | $558.6M | ||
| Q4 24 | $329.1M | $536.6M | ||
| Q3 24 | $398.2M | $533.3M | ||
| Q2 24 | $453.5M | $528.1M | ||
| Q1 24 | $336.8M | $511.0M |
| Q4 25 | $-2.8M | $135.1M | ||
| Q3 25 | $-2.6M | $111.1M | ||
| Q2 25 | $31.4M | $90.3M | ||
| Q1 25 | $23.3M | $114.6M | ||
| Q4 24 | $352.0K | $117.0M | ||
| Q3 24 | $22.3M | $96.4M | ||
| Q2 24 | $38.9M | $88.4M | ||
| Q1 24 | $-17.4M | $102.6M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | 21.6% | ||
| Q3 25 | -0.9% | 21.5% | ||
| Q2 25 | 7.7% | 20.9% | ||
| Q1 25 | 7.7% | 20.3% | ||
| Q4 24 | -3.9% | 23.4% | ||
| Q3 24 | 7.5% | 21.1% | ||
| Q2 24 | 11.5% | 19.9% | ||
| Q1 24 | -7.0% | 20.4% |
| Q4 25 | -0.8% | 19.1% | ||
| Q3 25 | -0.7% | 16.8% | ||
| Q2 25 | 7.7% | 15.0% | ||
| Q1 25 | 6.2% | 20.5% | ||
| Q4 24 | 0.1% | 21.8% | ||
| Q3 24 | 5.6% | 18.1% | ||
| Q2 24 | 8.6% | 16.7% | ||
| Q1 24 | -5.2% | 20.1% |
| Q4 25 | $-0.11 | $4.65 | ||
| Q3 25 | $-0.10 | $3.86 | ||
| Q2 25 | $1.15 | $3.10 | ||
| Q1 25 | $0.86 | $3.67 | ||
| Q4 24 | $0.02 | $3.67 | ||
| Q3 24 | $0.82 | $3.01 | ||
| Q2 24 | $1.43 | $2.75 | ||
| Q1 24 | $-0.65 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $459.1M |
| Total Assets | $1.7B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $497.0M | ||
| Q3 25 | $23.7M | $285.4M | ||
| Q2 25 | $18.4M | $46.3M | ||
| Q1 25 | $8.3M | $441.4M | ||
| Q4 24 | $19.6M | $669.4M | ||
| Q3 24 | $17.3M | $656.9M | ||
| Q2 24 | $12.1M | $510.9M | ||
| Q1 24 | $20.6M | $407.0M |
| Q4 25 | $815.2M | $459.1M | ||
| Q3 25 | $818.2M | $293.6M | ||
| Q2 25 | $823.7M | $172.4M | ||
| Q1 25 | $794.4M | $593.6M | ||
| Q4 24 | $774.6M | $825.5M | ||
| Q3 24 | $766.4M | $881.4M | ||
| Q2 24 | $746.6M | $763.6M | ||
| Q1 24 | $713.2M | $671.5M |
| Q4 25 | $1.7B | $2.0B | ||
| Q3 25 | $1.7B | $1.8B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.5B | $1.9B | ||
| Q1 24 | $1.5B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $192.7M |
| Free Cash FlowOCF − Capex | $36.1M | $188.1M |
| FCF MarginFCF / Revenue | 10.0% | 26.6% |
| Capex IntensityCapex / Revenue | 7.7% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $192.7M | ||
| Q3 25 | $26.6M | $246.2M | ||
| Q2 25 | $21.1M | $148.5M | ||
| Q1 25 | $11.4M | $125.8M | ||
| Q4 24 | $64.2M | $190.7M | ||
| Q3 24 | $57.3M | $149.1M | ||
| Q2 24 | $50.2M | $116.4M | ||
| Q1 24 | $-36.2M | $152.7M |
| Q4 25 | $36.1M | $188.1M | ||
| Q3 25 | $66.0K | $235.5M | ||
| Q2 25 | $-7.2M | $142.4M | ||
| Q1 25 | $-22.6M | $115.8M | ||
| Q4 24 | $29.8M | $183.0M | ||
| Q3 24 | $26.8M | $138.5M | ||
| Q2 24 | $16.7M | $103.5M | ||
| Q1 24 | $-71.6M | $147.2M |
| Q4 25 | 10.0% | 26.6% | ||
| Q3 25 | 0.0% | 35.7% | ||
| Q2 25 | -1.7% | 23.6% | ||
| Q1 25 | -6.0% | 20.7% | ||
| Q4 24 | 9.1% | 34.1% | ||
| Q3 24 | 6.7% | 26.0% | ||
| Q2 24 | 3.7% | 19.6% | ||
| Q1 24 | -21.3% | 28.8% |
| Q4 25 | 7.7% | 0.6% | ||
| Q3 25 | 7.1% | 1.6% | ||
| Q2 25 | 6.9% | 1.0% | ||
| Q1 25 | 9.0% | 1.8% | ||
| Q4 24 | 10.4% | 1.4% | ||
| Q3 24 | 7.7% | 2.0% | ||
| Q2 24 | 7.4% | 2.4% | ||
| Q1 24 | 10.5% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 0.67× | 1.65× | ||
| Q1 25 | 0.49× | 1.10× | ||
| Q4 24 | 182.29× | 1.63× | ||
| Q3 24 | 2.57× | 1.55× | ||
| Q2 24 | 1.29× | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
